ERBB2 and gastric cancer: One of the most promising treatments is the antibody drug-conjugated trastuzumab deruxtecan (T-DXd) that showed antitumor activity also in patients with low levels of HER2 expression and prolonged OS in advanced HER2 positive gastric cancer resistant to other therapies, including trastuzumab [17,18].